MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice - MaaT Pharma

Download the poster

Previous PostMaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study
Next PostNovember 5, 2025: MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club